{
    "doi": "https://doi.org/10.1182/blood.V122.21.3753.3753",
    "article_title": "Allele-Specific Loss Of The Mir-15a/16-1 Cluster Correlates With ZAP70 Expression In CLL Patients With 13q Deletion ",
    "article_date": "November 15, 2013",
    "session_type": "602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster III",
    "abstract_text": "Chronic lymphocytic leukemia, the most common form of adult leukemia in the Western world, is characterized by a heterogeneous clinical course, with indolent or progressive forms that entail profoundly different approaches to treatment. The biomarkers useful to predict the clinical course of CLL encompass cytogenetic abnormalities, protein expression (ZAP70, CD38) and IGHV mutation status. Among the many molecular features characterizing biological and clinical aspects of CLL patients, deletion of 13q14 and down-regulation of its related microRNAs (miR-15a and miR-16-1) are the most frequent aberrations in CLL. The involvement of the miR-15a and mir-16-1 in CLL has been extensively described by in vivo and in vitro studies and the genomic region encompassing the miR cluster results frequently deleted, but the mechanisms that regulate the expression of these miRs in CLL are still poorly understood. Here we demonstrate that the G to A single nucleotide polymorphism (SNP) rs115069827 prevents the maturation of miR-15a by reducing the binding of the DROSHA complex to the pri-microRNA 15a/16-1. The study of this functional SNP allowed us to discover a novel mechanism of transcription of the miR-15a/16-1 cluster, independent of DLEU2, its host gene. We demonstrate that the genomic region immediately upstream of the miR-15a/16-1, including the SNP, acts as transcriptional activator. The miR-15a/16-1 cluster is transcribed by allele-specific mechanisms: transcription of one allele is driven by the RNA Polymerase II at the DLEU2 promoter, while the other allele is transcribed by a mechanism that involves occupancy of the newly identified transcription activator region by RNA Polymerase III. Interestingly, the latter mechanism is dominant within CLL cells with mono-allelic 13q14 deletion and high expression of ZAP70 (Fisher's exact test p:0.0128) ( Table1 ). Moreover, in our patient cohorts (training set n=28, validation set n=19) there are CLL samples with cells carrying 13q14 deletions that did not encompass the miR-15a/16-1 locus. Almost all of these show high expression of ZAP70 (Fisher's exact test training set p:0.0055; validation set p:0.0374) and primiR regulation by RPIII, in the presence of both alleles of miR-15a/16-1 . By CNV analysis of a more telomeric region (\u223c30 kb, U59 DLEU2 region), that encompasses the second DLEU2 promoter, we demonstrate that these CLL cells carry a mono-allelic deletion of this region, which entails loss of the primiR regulation by the DLEU2 promoter ( occupied by RPII). Table 1 primiR 15a/16-1 transcritpion by RPII independent mechanism correlates with ZAP70 expression in 13q deleted CLL.  Sample . FISH . Copy number variation (CNV) . ZAP70 . IGVH . Relative expression after \u03b1 amanitin treatment (2\u00b5g/ml) . primiR 15a/16-1 RNA Polymerase . U59 DLEU1 . miR 15a/16-1 . primiR 15a/16-1 . pretRNAtyr . preACTB preGAPDH . LLC31 13q  nd - M \u2193 = \u2193 II LLC42 NK  +/- - M = \u2193 \u2193 III LLC18 13q  +/- - M \u2193 = \u2193 II LLC07 13q  +/- - U \u2193 = = II LLC45 NK  +/- - M \u2193 = \u2193 II LLC50 NK  +/- - M = = \u2193 III LLC52A 13q  +/- - M = nd \u2193 III LLC61 13q  +/- - M \u2193 = \u2193 II LLC81 13q  +/- - M \u2193 = \u2193 II LLC47 13q  +/- - M = = \u2193 III LLC03A NK  +/- - M \u2193 = nd II CLL4Tw 13q  +/- - M \u2193 = \u2193 II CLL3Tw NK  +/- + M = = \u2193 III LLC04 12tri/13q +/- +/+ + U = \u2193 \u2193 III LLC64 13q  +/- + U = \u2193 \u2193 III LLC70 13q +/+ +/+ + U = = \u2193 III LLC36 13q  +/- + M = \u2193 \u2193 III LLC80 NK +/- +/+ + M = = \u2193 III LLC17A NK +/- +/+ + nd = nd \u2193 III Sample . FISH . Copy number variation (CNV) . ZAP70 . IGVH . Relative expression after \u03b1 amanitin treatment (2\u00b5g/ml) . primiR 15a/16-1 RNA Polymerase . U59 DLEU1 . miR 15a/16-1 . primiR 15a/16-1 . pretRNAtyr . preACTB preGAPDH . LLC31 13q  nd - M \u2193 = \u2193 II LLC42 NK  +/- - M = \u2193 \u2193 III LLC18 13q  +/- - M \u2193 = \u2193 II LLC07 13q  +/- - U \u2193 = = II LLC45 NK  +/- - M \u2193 = \u2193 II LLC50 NK  +/- - M = = \u2193 III LLC52A 13q  +/- - M = nd \u2193 III LLC61 13q  +/- - M \u2193 = \u2193 II LLC81 13q  +/- - M \u2193 = \u2193 II LLC47 13q  +/- - M = = \u2193 III LLC03A NK  +/- - M \u2193 = nd II CLL4Tw 13q  +/- - M \u2193 = \u2193 II CLL3Tw NK  +/- + M = = \u2193 III LLC04 12tri/13q +/- +/+ + U = \u2193 \u2193 III LLC64 13q  +/- + U = \u2193 \u2193 III LLC70 13q +/+ +/+ + U = = \u2193 III LLC36 13q  +/- + M = \u2193 \u2193 III LLC80 NK +/- +/+ + M = = \u2193 III LLC17A NK +/- +/+ + nd = nd \u2193 III View Large Overall these data may clarify important genetic features of the major subgroup of CLL patients and highlight the concept that regulation of the expression of the miR-15a/16-1 is the critical event in CLL pathogenesis. Being ZAP70 high expression associated with poor prognosis in CLL, we show that the concomitant presence of different mechanisms of transcriptional regulation of miR-15a and miR-16-1 could have different impacts on the pathogenesis/progression of the CLL. nd : not determined, M : IGVH mutated, U : IGVH unmutated, CNV : Copy number variation, NK , normal karyotype; 13q , deletion of 13q chromosome region; 12tri , 12 trisomy; +/+ , presence of both alleles; +/- , monoallelic deletion; - , ZAP70\u226420%; + , ZAP70>20%; \u2193 , downregulation of RNA expression after \u03b1 amanitin treatment; = , no change in the RNA expression after \u03b1 amanitin treatment; II , RPII; III , RPIII. Fisher's test: RPIII vs ZAP70, p:0.0128; RPIII vs IGVH, p:0.576 Disclosures: No relevant conflicts of interest to declare.",
    "topics": [
        "alleles",
        "chromosome 13q deletion",
        "infectious mononucleosis",
        "zap-70 kinase",
        "micrornas",
        "transcription coactivator",
        "biological markers",
        "chronic b-cell leukemias",
        "chronic lymphocytic leukemia",
        "dna-directed rna polymerase"
    ],
    "author_names": [
        "Angelo Veronese",
        "Felice Pepe",
        "Jessica Chiacchia",
        "Sara Pagotto",
        "Serena Veschi",
        "Mirco Di marco",
        "Andrea D'Argenio",
        "Marco Russo",
        "Barbara Vannata",
        "Idana Innocenti",
        "Giuseppe Leone, MD",
        "Francesco Autore",
        "Dorothee Wernicke-Jameson",
        "Fabio Verginelli",
        "Laura Rassenti, PhD",
        "Thomas J. Kipps, MD, PhD",
        "Renato Mariani-Costantini",
        "Luca Laurenti, MD",
        "Carlo M. Croce, MD",
        "Rosa Visone, Ph.D"
    ],
    "author_dict_list": [
        {
            "author_name": "Angelo Veronese",
            "author_affiliations": [
                "G. d'Annunzio University, Chieti-Pescara, Italy, "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Felice Pepe",
            "author_affiliations": [
                "\u201cG. d'Annunzio\u201d University, Chieti-Pescara, Italy, "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jessica Chiacchia",
            "author_affiliations": [
                "\u201cG. d'Annunzio\u201d University, Chieti-Pescara, Italy, "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Sara Pagotto",
            "author_affiliations": [
                "\u201cG. d'Annunzio\u201d University, Chieti-Pescara, Italy, "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Serena Veschi",
            "author_affiliations": [
                "\u201cG. d'Annunzio\u201d University, Chieti-Pescara, Italy, "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mirco Di marco",
            "author_affiliations": [
                "\u201cG. d'Annunzio\u201d University, Chieti-Pescara, Italy, "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Andrea D'Argenio",
            "author_affiliations": [
                "\u201cG. d'Annunzio\u201d University, Chieti-Pescara, Italy, "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Marco Russo",
            "author_affiliations": [
                "\u201cG. d'Annunzio\u201d University, Chieti-Pescara, Italy, "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Barbara Vannata",
            "author_affiliations": [
                "Hematology, Catholic University of Rome, Rome, Italy, "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Idana Innocenti",
            "author_affiliations": [
                "Universit\u00e0 Cattolica, Roma, Italy, "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Giuseppe Leone, MD",
            "author_affiliations": [
                "Istituto di Ematologia, Universit\u00e0 Cattolica S. Cuore, Rome, Italy, "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Francesco Autore",
            "author_affiliations": [
                "Universit\u00e0 Cattolica, Roma, Italy, "
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Dorothee Wernicke-Jameson",
            "author_affiliations": [
                "The Ohio State University, Columbus, OH, USA, "
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Fabio Verginelli",
            "author_affiliations": [
                "\u201cG. d'Annunzio\u201d University, Chieti-Pescara, Italy, "
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Laura Rassenti, PhD",
            "author_affiliations": [
                "Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA, "
            ],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Thomas J. Kipps, MD, PhD",
            "author_affiliations": [
                "University of California, San Diego, Moores Cancer Center, La Jolla, CA, USA, "
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Renato Mariani-Costantini",
            "author_affiliations": [
                "\u201cG. d'Annunzio\u201d University, Chieti-Pescara, Italy, "
            ],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Luca Laurenti, MD",
            "author_affiliations": [
                "Department of Hematology, Catholic University of Rome, A. Gemelli Hospital, Rome, Italy, "
            ],
            "author_rank": 18,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Carlo M. Croce, MD",
            "author_affiliations": [
                "The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA, "
            ],
            "author_rank": 19,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Rosa Visone, Ph.D",
            "author_affiliations": [
                "Department of Medicine, Dentistry and Biotechnology, \u201cG. d'Annunzio\u201d University, Chieti-Pescara, Italy"
            ],
            "author_rank": 20,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-26T09:34:44",
    "is_scraped": "1"
}